CAPOBIANCO, Marco
CAPOBIANCO, Marco
A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity
2018-01-01 Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J
A real-world study of Alemtuzumab in a cohort of Italian patients
2019-01-01 Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A
Mitoxantrone-related acute myeloid leukaemia, induced one year after the discontinuation of mitoxantrone therapy
2006-01-01 Capobianco, M; Malucchi, S; Bosa, M; Fava, C; Avonto, L; Bertolotto, A
MS Italian patients manifesting natalizumab-related PML between 2009 and 2014. Report of the Italian group for MS-PML study
2015-01-01 De Rossi, N; Cordioli, C; Gerevini, S; Amato, MP; Bandini, F; Cavalla, P; Clerico, M; Capobianco, M; Deotto, L; De Riz, MA; Ferrari, E; Scarpazza, C; Fusco, ML; Ghezzi, A; Grimaldi, L; Lugaresi, A; Moiola, L; Perrone, P; Prosperini, L; Rezzonico, M; Rovaris, M; Salemi, G; Salvetti, M; Santuccio, G; Solaro, C; Tortorella, C; Capra, R
Shift from fingolimod to alemtuzumab: what happens next?
2018-01-01 Frau, J; Sacca, F; Signori, A; Baroncini, D; Fenu, G; Annovazzi, P; Capobianco, M; Signoriello, E; Laroni, A; La Gioia, S; Sartori, A; Maniscalco, GT; Bonavita, S; Clerico, M; Russo, CV; Gallo, A; Lapucci, C; Sormani, MP; Cocco, E
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience
2017-01-01 Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L
Switching to alemtuzumab from fingolimod or other therapies: impact of wash-out period on disease activity
2017-01-01 Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, G; Cordioli, C; Rasia, S; Clerico, M; Cocco, E; Frau, J
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity | 2018 | Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J | |
| A real-world study of Alemtuzumab in a cohort of Italian patients | 2019 | Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A | |
| Mitoxantrone-related acute myeloid leukaemia, induced one year after the discontinuation of mitoxantrone therapy | 2006 | Capobianco, M; Malucchi, S; Bosa, M; Fava, C; Avonto, L; Bertolotto, A | |
| MS Italian patients manifesting natalizumab-related PML between 2009 and 2014. Report of the Italian group for MS-PML study | 2015 | De Rossi, N; Cordioli, C; Gerevini, S; Amato, MP; Bandini, F; Cavalla, P; Clerico, M; Capobianco, M; Deotto, L; De Riz, MA; Ferrari, E; Scarpazza, C; Fusco, ML; Ghezzi, A; Grimaldi, L; Lugaresi, A; Moiola, L; Perrone, P; Prosperini, L; Rezzonico, M; Rovaris, M; Salemi, G; Salvetti, M; Santuccio, G; Solaro, C; Tortorella, C; Capra, R | |
| Shift from fingolimod to alemtuzumab: what happens next? | 2018 | Frau, J; Sacca, F; Signori, A; Baroncini, D; Fenu, G; Annovazzi, P; Capobianco, M; Signoriello, E; Laroni, A; La Gioia, S; Sartori, A; Maniscalco, GT; Bonavita, S; Clerico, M; Russo, CV; Gallo, A; Lapucci, C; Sormani, MP; Cocco, E | |
| Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience | 2017 | Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L | |
| Switching to alemtuzumab from fingolimod or other therapies: impact of wash-out period on disease activity | 2017 | Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, G; Cordioli, C; Rasia, S; Clerico, M; Cocco, E; Frau, J |